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Background: Extrapulmonary tuberculosis (EPTB) and most pediatric TB cannot be diagnosed using sputum-based
assays. The epidemiological impact of different strategies to diagnose EPTB and pediatric TB is unclear.
Methods: We developed a dynamic epidemic model of TB in a hypothetical population with epidemiological
characteristics similar to India. We evaluated the impact of four alternative diagnostic test platforms on adult
EPTB and pediatric TB mortality over 10 years: (1) Nucleic acid amplification test optimized for diagnosis of EPTB
(“NAAT-EPTB”); (2) NAAT optimized for pediatric TB (“NAAT-Peds”); (3) more deployable NAAT for sputum-based
diagnosis of adult pulmonary TB (“point-of-care (POC) sputum NAAT”); and (4) more deployable NAAT capable of
diagnosing all forms of TB using non-invasive, non-sputum specimens (“POC non-sputum NAAT”).
Results: NAAT-EPTB lowered adult EPTB mortality by a projected 7.6% (95% uncertainty range [UR]: 6.5-8.8%).
NAAT-Peds lowered pediatric TB mortality by 6.8% (UR: 4.9-8.4%). POC sputum NAAT, though only able to diagnose
pulmonary TB, reduced projected pediatric TB deaths by 13.3% (UR: 4.6-15.7%) and adult EPTB deaths by 8.4% (UR
2.0-9.3%) simply by averting transmission of disease. POC non-sputum NAAT had the greatest effect, lowering
pediatric TB mortality by 34.7% (UR: 26.8-38.7), and adult EPTB mortality by 38.5% (UR: 30.7-41.2). The relative impact
of a POC sputum NAAT (i.e., enhanced deployability) versus NAAT-EPTB (i.e., enhanced ability to specifically diagnose
TB-NSP) on adult EPTB mortality depends most strongly on factors that influence transmission, with settings of higher
transmission (e.g., higher per-person transmission rate, lower diagnostic rate) favoring POC sputum NAAT.
Conclusion: Although novel tests for pediatric TB and EPTB are likely to reduce TB mortality, major reductions in
pediatric and EPTB incidence and mortality also require better diagnostic tests for adult pulmonary TB that reach a
larger population.
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Improved diagnostic tests are needed to reduce the tremen-
dous burden of morbidity and mortality due to tuberculosis
(TB), a disease that affects 8.6 million people and kills 1.3
million every year [1]. In 2010, Xpert MTB/RIF (“Xpert”), a
high-sensitivity rapid molecular test, was released and soon
thereafter endorsed by the World Health Organization
(WHO) for the diagnosis of adult pulmonary TB [2-4].
While pulmonary TB accounts for the largest burden of
disease and Xpert as well as most other TB diagnostics are
designed to use sputum as a biological specimen, at least
20% of all adults (up to 30-40% in HIV patients) – and* Correspondence: claudia.denkinger@mail.mcgill.ca
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article, unless otherwise stated.most children with TB – either cannot produce sufficient
sputum (“sputum-scarce”), do not have sufficient bacilli in
their sputum to be detected, or have extrapulmonary TB
(EPTB) [5-8]. EPTB and pediatric TB result in significant
morbidity and mortality dependent on the organs affected
(e.g., central nervous system) and due to the difficulty in
achieving a diagnosis [9,10]. Therefore, further research on
improving existing tests and developing novel tests for
pediatric TB and EPTB is necessary.
The most recent WHO guideline recommends Xpert for
use in children and individuals with certain subsets of EPTB
[11,12]. However, the evidence base for this recommenda-
tion is considered to be very low-quality, and the accuracy
of Xpert in its current version is insufficient for subsets of
EPTB (e.g. pleural TB and TB meningitis) [11,12].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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approach could be an “optimized” Xpert or other nucleic
acid amplification test (NAAT) capable of detecting
M. tuberculosis with higher sensitivity in specimens other
than sputum (e.g. tissue) for example through improved
sample processing and DNA extraction. Another approach
targeting the diagnosis of pulmonary TB in children and
others who cannot produce good sputum, might be an
improved non-sputum based assay (possibly optimized
Xpert or other NAAT) using more easily accessible
specimens (e.g. nasopharyngeal samples) [11,13].
A third approach to improving the control of pediatric
and EPTB is to develop more deployable tests for adult
pulmonary TB, reasoning that children and immuno-
compromised individuals are at highest risk of developing
active TB from recent transmission, and diagnosis and
treatment strategies capable of reducing TB transmission in
a community might have important indirect effects on
pediatric and extrapulmonary TB [14]. The ideal assay,
however, would be a test with improved diagnosis for
pulmonary TB, “sputum scarce” TB, and EPTB in adults
and children alike using clinical specimens other than
sputum (e.g., blood or urine) on a deployable (able to be
rolled out at microscopy center level) and sensitive
platform linked to rapid treatment initiation [15].Figure 1 Study flow diagram. Dashed boxes contain subjects that are inf
HIV status, the type of tuberculosis (TB – pulmonary or extrapulmonary) and by
multidrug-resistant [MDR], and extensively-drug resistant [XDR]); these delineatioTo evaluate the comparative effectiveness of such differ-
ent diagnostic approaches for EPTB and pediatric TB and
evaluate them against a current baseline scenario with
smear microscopy and alternatively with Xpert for adult
pulmonary TB at the district level health care, we con-
structed a dynamic epidemic model of TB in a generalizable
population, estimating ten-year EPTB and childhood TB
incidence and mortality if four hypothetical but emblematic
tests for EPTB and pediatric TB could be implemented.
Methods
Model structure
We built a compartmental model using ordinary differential
equations to describe a mature tuberculosis epidemic in a
stable, homogeneously mixing population structured by age
and HIV status. Figure 1 describes the basic structure of the
model; a more detailed description is found in the supple-
ment. Given that the hypothetical assays we evaluate should
have impact across the epidemiological contexts of greatest
TB burden, we modeled a paradigmatic population with an
incidence of drug-susceptible (181/100,000 per year) and
drug-resistant TB (2.1% MDR among new cases) and an
HIV prevalence similar to that of India (0.3%) [16]. We used
data from World Health Organization (WHO) notifications
and other published literature to inform parameters in ourectious. The compartments are also defined by the individual’s age,
the TB drug susceptibility pattern (sensitive, isoniazid [INH]-monoresistant,
ns are not shown in the diagram for simplicity.
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tests for pediatric TB relative to those for adult pulmonary
TB, we made liberal assumptions about the percentage of
TB that occurs in children (taking into account the likely
substantial underreporting of pediatric TB) [19-29].
Our primary modeling aim was to assess the maximum
potential impact of a test that has enhanced capacity to
diagnose clinical manifestations of TB that are not readily
diagnosable with sputum-based tests. Our primary out-
comes were the projected incidence and mortality due to
TB overall, pediatric TB, and adult EPTB.
Pediatric and extrapulmonary TB are heterogeneous
entities, including clinical sites as diverse as lymph nodes,
bone, and the central nervous system, each with different
degrees of severity and ability to be diagnosed by currently
available means. As no model can fully account for such
clinical diversity, we represent these heterogeneous mani-
festations as a single entity, labeled “TB with no sputum
production” (TB-NSP), that reflects a weighted average of
all TB clinical manifestations that are not readily diagnos-
able by sputum-based assays. We presume that the
proportion of active TB consisting of TB-NSP is 85% in
children (age 0–15) [6,30], of which about 70% is in fact
pulmonary TB (with and without extrapulmonary compo-
nents) that cannot be diagnosed because a diagnostic
sputum sample cannot be obtained, and the remaining 30%Table 1 Parameters
Definition
Non-TB death rate per year
TB mortality per year
Transmission events per infectious person-year in year 10*
Partial immunity afforded by previous infection
Proportion of TB infections progressing rapidly to active TB
Endogenous reactivation rate per year
Rate of self-cure in active TB per year
Percent of patients without access to diagnostics
Sensitivity of current diagnostic standard for PTB
Sensitivity of current diagnostic standard for EPTB
Sensitivity of novel test methods for PTB
Proportion of adults that develop EPTB or sputum scarce PTB in
Proportion of children that develop EPTB or sputum scarce PTB independent
of HIV status (weighted average among different age groups)
Abbreviations: TB tuberculosis, NAAT nucleic-acid amplification test, EPTB extrapulmo
are estimated to be about half as infectious as HIV-negative patients).is EPTB. In the adult population, we assume TB-NSP
constitutes about 18% in HIV-uninfected adults and 35% in
HIV-infected adults (Table 1) [6,31,32].
Model calibration
We first established a baseline “year zero”, modeled as a
scenario representative of the current TB epidemic in India
[18]. We initiated the model at steady state 65 years prior
to year zero (e.g., 1950, if year zero corresponds to 2015),
calibrating the TB transmission rate (number of secondary
infections per smear-positive person-year) to match India’s
WHO-estimated TB incidence (181 per 100,000/year in
2011) [18]. To provide a realistic epidemic trajectory, we
reduced the overall TB transmission rate to a degree
sufficient to generate a 2% per year decline in TB incidence,
the globally estimated average, five years before introducing
the diagnostic interventions [18].
Diagnostic algorithms
At baseline, we assumed a “standard” diagnostic approach
for individuals suspected of having adult pulmonary TB;
this approach may consist of sputum examinations, ancil-
lary diagnostic tests (e.g. chest X-ray, antibiotic trials), and
clinical judgment [33]. We calibrated the sensitivity of this
“standard approach” to a value (i.e. 80%) that provided a
reasonable estimate of TB case detection rate (model valueHIV status Value Range References
all 0.022 0.02-0.025
HIV negative 0.15 0.1-0.22 [1,19]
HIV positive 0.50 0.4-0.7 [20]
all 8.95
HIV negative 0.45 0.4-0.55 [21,22]
HIV positive 0 0-0.2
HIV negative 0.14 0.05-0.14 [23]
HIV positive 0.25 0.16-0.27
HIV negative 0.0005 0.08-1.4 x10−3 [24]
HIV positive 0.05 0.03–0.05
HIV negative 0.1 0.08-0.28 [25]
HIV positive 0 0-0.2
all 0.1 0.05-0.25 [26]
all 0.80 0.6-0.9 [18,33]
all 0.6 0.4-0.8
all 0.95 0.75-0.98 [27-29]
HIV negative 0.18 0.15-0.25 [31,32]
HIV positive 0.35 0.3-0.7
all 0.85 0.6-0.9 [5]
nary TB. *averaged over all patients with pulmonary TB (HIV-positive patients
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[17]. Diagnosis through this standard approach is assumed
to occur at a given constant rate; in calculating this rate,
we assumed that the delay in diagnosing TB-NSP would be
twice that for adult pulmonary TB because of the difficulty
in obtaining a sample from the site of infection (e.g. pleural
aspirate or gastric fluid) for diagnosis [34].
In our analytic scenarios, we then enhanced this baseline
diagnostic algorithm with platforms designed to improve
diagnosis of TB-NSP through different combinations of
(a) optimized detection of TB using clinical specimens
other than sputum and/or (b) enhanced deployability of the
assay itself:
Xpert MTB/RIF for adult pulmonary TB
Starting in year zero, we augmented the “standard” diag-
nostic approach with Xpert for adult pulmonary TB for
adult pulmonary TB. We assumed that Xpert would
increase the overall sensitivity of the standard approach for
the diagnosis of adult pulmonary TB – incorporating all
existing diagnostic tests, plus clinical judgment – from 80%
to 95% (i.e., detecting 75% of TB cases who would other-
wise be missed with 98% specificity) [33,35]. We assumed
that given Xpert’s current infrastructure requirements (e.g.,
constant power supply), it would be implemented in district
level health centers and therefore would reach 15%, 30%
and 30% of new, previously treated, and failure cases
respectively (i.e. deployability limited to district level health
centers). The remainder of cases continued to be diagnosed
with the standard approach.
Optimized diagnostic approaches
We compared the impact of Xpert for adult pulmonary TB
to that of four hypothetical tests that were designed to illus-
trate important test characteristics (e.g., components of a
“target product profile”) and tradeoffs between deployability
and ability to diagnose TB-NSP (and may or may not
involve an Xpert like algorithm). We use the term “deploy-
ability” to denote the level of the healthcare system at
which a diagnostic test can be implemented, and thus the
proportion of the healthcare-seeking population that could
reasonably be tested – assuming that tests implemented at
more peripheral levels (e.g., microscopy centers) could
reach a wider population than those implemented only in
centralized laboratories. To maintain generalizability, we
did not attempt to model any specific test currently in
development. The four hypothetical tests were:(1).“NAAT Peds” – same accuracy (i.e. 95% sensitivity
and 98% specificity), deployability and ability to
diagnose adult pulmonary TB as Xpert but capable
of diagnosing, in addition, 70% of all forms of
TB-NSP with a respiratory component in children(e.g., using nasopharyngeal fluid but not able to
diagnose, for example, TB meningitis);
(2).“NAAT-EPTB” – deployability equal to Xpert (owing
to the need for obtaining invasive specimens such as
cerebrospinal fluid or gastric fluid) but capable of
diagnosing both TB-NSP and pulmonary TB with the
same accuracy as Xpert (i.e. 95% sensitivity and 98%
specificity), through use of non-respiratory samples;
(3).“POC sputum NAAT” – same sensitivity and
specificity as Xpert for adult pulmonary TB, only
more portable and less dependent on existing
infrastructure (i.e. deployable at microscopy center
level); modeled as reaching 50%, 80%, and 100% of
new, previously treated, and failure cases
respectively;
(4).“POC non-sputum NAAT” – similar to POC sputum
NAAT (same sensitivity and specificity as Xpert) but
using a more accessible clinical specimen (e.g., urine or
finger-prick blood) and thus capable of diagnosing both
pulmonary TB and TB-NSP, with the same speed for
both as it does not require an invasive sample but
without rifampin resistance detection [14,15].
Sensitivity analysis
We conducted one-way sensitivity analyses on all model
parameters taking as the outcome the difference in adult
EPTB mortality comparing NAAT-EPTB (improved detec-
tion of TB-NSP through access of non-pulmonary sites) to
POC sputum NAAT (improved detection through higher
deployability of a sputum-based test). The ranges of the
parameters are based on the available literature and possible
advances in the near future, as outlined in Additional file 1:
Table S1. To estimate variability associated with simultan-
eous changes in all parameters, we also conducted a
probabilistic uncertainty analysis using Latin Hypercube
Sampling (Additional files 1 and 2 detail in the supplement).
Results
Impact on TB incidence
In the absence of any improvement in TB diagnosis, we
projected, in year ten, 44.8 TB cases and 9.4 deaths per
100,000 in children and 89.5 cases and 22.8 deaths in adults
(Table 2). If Xpert for adult pulmonary TB was scaled up in
year zero for 15% of new and 30% of previously treated
cases, TB incidence fell from this baseline by 5.0% in
children (95% uncertainty range [UR]: 1.6-6.1%) and 4.0%
in adults (UR 1.0-4.5%). Implementation of Xpert for adult
pulmonary TB after 10 years did not change the proportion
of TB that was TB-NSP (30% in adults, 78% in children).
Replacement of Xpert for adult pulmonary TB with POC
sputum NAAT (i.e., a more deployable but equally accurate
sputum-based test) resulted in more TB being diagnosed
and treated, thus reducing pediatric TB incidence by 13.8%
(UR 4.6-16.3%) and adult TB incidence by 11.1% (UR 2.7-
Table 2 Projected tuberculosis outcomes
10-year projected tuberculosis outcomes
Incidence per 100,000 Prevalence per 100,000 Mortality per 100,000
Adult total Adult EPTB Children Adult total Adult EPTB Children Adult total Adult EPTB Children
N (%
reduction*)
N (%
reduction*)
N (%
reduction*)
N (%
reduction*)
N (%
reduction)
N (%
reduction*)
N (%
reduction*)
N (%
reduction*)
N (%
reduction*)
Existing standard 89.5 (Ref) 13.9 (Ref) 44.8 (Ref) 114.8 (Ref) 34.4 (Ref) 62.8 (Ref) 22.8 (Ref) 7.3 (Ref) 9.4 (Ref)
Xpert for adult
pulmonary TB
86.0 (4.0%) 13.4 (3.7%) 42.6 (5.0%) 109.3 (4.8%) 33.2 (3.5%) 59.8 (4.9%) 21.8 (4.5%) 7.1 (3.0%) 8.9 (4.8%)
NAAT-Peds 86.0 (4.0%) 13.4 (3.7%) 42.6 (5.0%) 109.2 (4.9%) 33.1 (3.9%) 58.5 (6.9%) 21.8 (4.5%) 7.1 (3.3%) 8.7 (6.8%)
NAAT-EPTB 86.0 (4.0%) 13.4 (3.7%) 42.6 (5.0%) 107.8 (6.1%) 31.7 (7.9%) 58.0 (7.7%) 21.4 (5.9%) 6.7 (7.6%) 8.7 (7.6%)
POC NAAT sputum 79.6 (11.1%) 12.5 (10.2%) 38.6 (13.8%) 99.8 (13.0%) 31.0 (9.8%) 54.4 (13.4%) 20.0 (12.2%) 6.7 (8.4%) 8.1 (13.3%)
POC NAAT non-
sputum
80.2 (10.4%) 12.6 (9.6%) 39.0 (13.0%) 90.5 (21.2%) 21.1 (38.8%) 41.0 (34.7%) 18.0 (21.3%) 4.5 (38.5%) 6.1 (34.7%)
Abbreviations: POC point of care, NAAT nucleic-acid amplification test, EPTB extrapulmonary TB. *compared to existing standard = Ref. Incidence, prevalence and
mortality for children and adults by year ten with different interventions.
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could not detect rifampin resistance (i.e., POC non-sputum
NAAT) had nearly similar impact on incidence: 13.0% (UR
4.0-15.5%, from 44.8 to 39.0 cases per 100,000/year) reduc-
tion in children and 10.4% (UR 2.3-11.4%; from 89.5 to 80.2
cases per 100,000/year) in adults (Figure 2A, Table 2). In
contrast, NAAT-EPTB and NAAT-Peds did not reduce TB
incidence beyond the effect of Xpert for adult pulmonary
TB alone (Table 2), reflecting model assumptions that
EPTB is not infectious and TB in children is substantially
less infectious than pulmonary TB in adults. NAAT-EPTB
also had only a small incremental effect on adult TB-NSP
prevalence over Xpert alone (4.5% reduction).
Impact on TB mortality
After 10 years, Xpert for adult pulmonary TB reduced
deaths by a projected 4.8% in children (UR 1.6-5.9%) and
4.5% in adults (UR 1.6-5.6%) (Figure 2B, Table 2), closely
mirroring reductions in incidence. All diagnostic tests for
TB-NSP had substantially greater impact on TB mortality
than on incidence. The addition of detection of TB-NSP in
children with NAAT-Peds and in adults with NAAT-EPTB
enhanced mortality reductions to 6.8% (UR 4.9-8.4%) in
children and 5.9% (UR 3.9-7.3%) in adults, respectively.
NAAT-EPTB and POC sputum NAAT achieved similar
reductions in adult EPTB mortality after 10 years (7.6% [UR
6.5-8.8%] and 8.4% [UR 2.0-9.3%], respectively), but through
different mechanisms: NAAT-EPTB resulted directly in
better treatment of adult EPTB, whereas POC sputum
NAAT reduced TB transmission and thus the number of
future cases of adult EPTB. Since its mechanism was more
direct, NAAT-EPTB achieved its effect on mortality more
rapidly (Figure 3A). However, since the majority of TB is
adult pulmonary TB, POC sputum NAAT had a much
greater effect on overall adult TB mortality (12.2% reduction
[UR 4.5-14.8%] compared to 5.9% [UR 3.9-7.3%] with
NAAT-EPTB). Similar to the NAAT-EPTB for adult EPTBmortality, the NAAT-Peds outperformed POC sputum
NAAT in early years, but POC sputum NAAT led to greater
reductions in TB mortality – and even pediatric-specific TB
mortality – over time: 13.3% [UR 4.6-15.7%] versus 6.8%
[UR 4.9-8.4%] at ten years (Figure 3B).
POC non-sputum NAAT had the greatest impact on TB
mortality, reducing pediatric TB mortality by 34.7% (UR
26.8-38.7%; from 9.4 to 6.1 deaths per 100,000/year) and
adult EPTB mortality by 38.5% (UR 30.7-41.2; from 7.3 to
4.5 deaths per 100,000/year).
Sensitivity analysis
We focused our primary sensitivity analysis around the
comparison of POC sputum NAAT (i.e., enhanced deploy-
ability) versus NAAT-EPTB (i.e., enhanced ability to specif-
ically diagnose TB-NSP). The relative impact of these two
tests on adult EPTB mortality depends most strongly on
factors that influence transmission, with settings of higher
transmission (e.g., higher per-person transmission rate,
lower diagnostic rate) favoring POC sputum NAAT
(Figure 4). Since the sensitivity of the existing diagnostic
standard is much higher for adult pulmonary TB than for
TB-NSP, the impact of POC sputum NAAT depends more
strongly on the sensitivity of the existing standard than does
NAAT-EPTB. No one-way parameter variation across the
ranges in Additional file 1: Table S1 changed the absolute
difference in mortality by more than 1.2 cases per 100,000
per year. Further sensitivity analyses, including a 3-way
sensitivity analysis on the sensitivity of the existing standard
for PTB, the incremental sensitivity of the novel test and
the diagnostic rate, are reported in the supplement.
Discussion
This transmission model of a TB epidemic in a defined
population suggests that novel assays capable of diagnosing
TB-NSP in addition to TB that is diagnosed through sputum
examination may generate important (3-8%) reductions in
Figure 2 Impact of different tests on pulmonary and extrapulmonary TB (A) incidence and (B) mortality in adults and children.
Trajectory of (A) overall tuberculosis (TB) incidence and (B) mortality over 10 years without further intervention (maroon line), with introduction
of Xpert for adult pulmonary TB (green line; coverage 15%, 30%, 30% among new, previously treated and failure cases) and introduction of POC
sputum NAAT (purple line; coverage of 50%, 80%, 100%). In addition, we project the incremental impact of POC-non-sputum NAAT that was
optimized for detection of both pulmonary TB and extrapulmonary TB (EPTB) (orange line) using non-invasive samples thus eliminating a delay
in diagnosis of EPTB and being deployed at the same level of coverage as POC sputum NAAT.
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ever, greater impact on pediatric TB and EPTB mortality
(10-15%) may be achievable by deploying tests capable of
detecting adult pulmonary TB more widely (i.e., by reducing
pediatric and extrapulmonary TB indirectly through
reducing transmission). Nevertheless, dramatic reductions in
incidence and mortality are unlikely unless a novel test can
be developed that cannot only detect TB-NSP but do so
using a deployable platform on clinical specimens other than
sputum (e.g., hypothetical urine or finger-prick blood assay).
The indirect effect of a more deployable Xpert-like spu-
tum test on pediatric TB (i.e. POC sputum NAAT) on chil-
dren is particularly noteworthy. TB in children is acquiredpredominantly from adults and very young children have a
greater risk for progression to active disease [36]. Thus, in-
fection and disease in young children are a measure of TB
transmission, and tests (e.g., POC sputum NAAT) that add
no direct benefit to the diagnosis of TB in these children
may counter intuitively still have their greatest effect among
such young children, in whom nearly all active TB results
from recent transmission [37]. Comprehensive control
strategies for pediatric TB should therefore consider that
control of pediatric TB requires better tools for diagnosis of
the adult pulmonary manifestations responsible for most
transmission. Nevertheless, reductions in pediatric TB
incidence through reduced transmission are unlikely to be
Figure 3 Impact of different tests on mortality in (A) adult extrapulmonary and (B) pediatric tuberculosis. Trajectory of extrapulmonary
tuberculosis (TB) mortality in adults (A) and overall TB mortality in children (B) over 10 years without further intervention (maroon line), with
introduction of Xpert for adult pulmonary TB (green line; coverage 15%, 30%, 30% among new, previously treated and failure cases), POC sputum
NAAT (purple line; coverage of 50%, 80%, 100%), NAAT-EPTB (black line in A) and NAAT-Peds (black line in B; the latter two both at the same
coverage as Xpert). In addition, we project the incremental impact of POC-non-sputum NAAT (orange line).
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can save lives more immediately, and more directly –
remains a high priority. An optimized diagnostic and
preventive strategy for pediatric TB would include a more
sensitive test for pediatric forms of TB plus a more deploy-
able test for adult pulmonary TB that could both reduce
the infectious duration and hasten contact investigations in
which pediatric contacts of adult TB cases could be given
preventive therapy. Our model uses hypothetical tests,
however, efforts are ongoing to optimize Xpert for extra-
pulmonary specimens, develop an automated NAAT that
can be deployed at the microscopy center level and identify
biomarkers in urine, blood, breath or other more easily
accessible samples to make a POC non-sputum test a
reality [12,38,39].Prior models of Xpert for adult pulmonary TB have
projected a larger impact, specifically on mortality [40]. Our
model differs from those models in that we conceptualize a
“diagnostic attempt” not simply as the combined sensitivity
of a series of tests, but rather as a clinical decision-making
process that incorporates ancillary data (e.g., change in
symptoms over time) and therefore often occurs on a slower
time scale, but with increased overall sensitivity. This higher
sensitivity – including clinical or empiric diagnosis –
appears to reflect diagnostic reality, at least in settings with
trained clinicians and some ancillary testing (e.g., chest
X-ray) available [33]. As we incorporate clinical/empiric
diagnosis of TB, adding a single diagnostic test to the overall
diagnostic pathway results in a lower incremental benefit
(and as shown in the supplement a lower cost-effectiveness).
Figure 4 Sensitivity analysis. Absolute difference in extrapulmonary tuberculosis (EPTB) mortality in adults per 100,000 by year 10 if POC sputum
NAAT is compared to NAAT-EPTB varying one parameter at the time. Numbers in parentheses indicate parameter values at base case and the
range from lower and upper end over which the respective parameter is varied (while other parameters are kept constant). The analysis shows
that effect of POC sputum NAAT is primarily dependent on reducing transmission of adult pulmonary TB (PTB) and the sensitivity of the test for
existing standard for PTB in conjunction with the rate at which the test is used.
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certain limitations. In order to increase transparency and
generalizability, the model uses a hypothetical population
and is only calibrated to key input parameters reflective of
the current TB epidemiology in a population representative
of India. This model, therefore, does not account for the
complexity of the epidemiological scenario in India or any
other single specific location [17,18,41,42]. The model
structure also cannot fully capture the heterogeneity of TB
epidemics (for example, those driven primarily by HIV)
and the complexity of a diagnostic ecosystem with a large,
poorly functioning private sector alongside the public
sector as present in India [42-44]. Furthermore, the amount
of overtreatment in children is also considered to be
sizeable but poorly defined. A more accurate test could
curb overtreatment and result in more appropriate diagno-
sis and treatment, potentially improving effectiveness
beyond that estimated here. By excluding the potential
benefit of limiting overtreatment, we may underestimate
the effectiveness of testing in children in these settings.Conclusions
In conclusion, diagnostic tests for pediatric TB and EPTB
remain a key research priority, as they are likely to have
substantial additive impact on mortality over current
diagnostic tests that perform insufficiently. These tests are
expected to have large market potential. Nevertheless, in
the long run, the most effective way to reduce mortality
from TB-NSP (and especially pediatric TB, which is highly
correlated with recent TB transmission) may be to deploy
diagnostic tests and other strategies capable of reducing TB
incidence as a whole. One such mechanism is to prioritize
tests that can be run on accessible clinical specimens (e.g.,
blood, urine) and systems to link individuals who testpositive directly to treatment. New diagnostic tests are an
essential component in reducing the tremendous burden of
pediatric and extrapulmonary TB, but elimination of this
burden will require a combined approach that also empha-
sizes reduction in TB transmission and rapid linkage to
care.Additional files
Additional file 1: Table S1. Supplementary information on model
structure, parameters and additional analyses.
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